SI-BONE, Inc. (NASDAQ:SIBN) Director Jeffrey W. Dunn Sells 3,377 Shares of Stock

SI-BONE, Inc. (NASDAQ:SIBN) Director Jeffrey W. Dunn sold 3,377 shares of the company’s stock in a transaction that occurred on Thursday, June 5th. The shares were sold at an average price of $19.05, for a total transaction of $64,331.85. Following the completion of the sale, the director now owns 17,354 shares of the company’s stock, valued at approximately $330,593.70. This trade represents a 16.29% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

SI-BONE Stock Down 0.8%

Shares of NASDAQ:SIBN opened at $18.90 on Friday. The company has a market cap of $805.42 million, a PE ratio of -20.54 and a beta of 0.82. The company has a debt-to-equity ratio of 0.22, a quick ratio of 7.22 and a current ratio of 8.25. The firm has a 50 day simple moving average of $16.10 and a 200 day simple moving average of $15.52. SI-BONE, Inc. has a 52 week low of $11.70 and a 52 week high of $20.05.

SI-BONE (NASDAQ:SIBN) last released its quarterly earnings data on Monday, May 5th. The company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.09. The firm had revenue of $47.29 million for the quarter, compared to analyst estimates of $45.13 million. SI-BONE had a negative net margin of 23.82% and a negative return on equity of 22.51%. As a group, research analysts expect that SI-BONE, Inc. will post -0.78 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the stock. Truist Financial upped their price target on shares of SI-BONE from $20.00 to $22.00 and gave the company a “buy” rating in a research report on Tuesday, May 6th. Needham & Company LLC restated a “buy” rating and issued a $24.00 price target on shares of SI-BONE in a research report on Tuesday, May 6th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $25.00 price target on shares of SI-BONE in a research report on Tuesday, May 6th.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Rhumbline Advisers increased its stake in SI-BONE by 3.0% in the 4th quarter. Rhumbline Advisers now owns 57,621 shares of the company’s stock valued at $808,000 after buying an additional 1,683 shares during the period. MetLife Investment Management LLC increased its stake in SI-BONE by 17.6% in the 4th quarter. MetLife Investment Management LLC now owns 27,421 shares of the company’s stock valued at $384,000 after buying an additional 4,104 shares during the period. Proficio Capital Partners LLC acquired a new position in SI-BONE in the 4th quarter valued at approximately $155,000. Deutsche Bank AG increased its stake in SI-BONE by 53.0% in the 4th quarter. Deutsche Bank AG now owns 36,268 shares of the company’s stock valued at $508,000 after buying an additional 12,561 shares during the period. Finally, VELA Investment Management LLC increased its stake in SI-BONE by 23.8% in the 4th quarter. VELA Investment Management LLC now owns 122,671 shares of the company’s stock valued at $1,720,000 after buying an additional 23,592 shares during the period. Institutional investors and hedge funds own 98.11% of the company’s stock.

SI-BONE Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.